CTLA4 and hypophysitis: As shown in Figure 1A, sequential and/or combined treatment with both PD1/PDL1 and CTLA4 inhibitors as compared to monotherapy with PD1/PDL1 or CTLA4 inhibitors was associated with a higher risk of hypophysitis (hazard ratio [HR] 2.27, 95% confidence intervals [CI] 1.09‐4.70, P = .028) with a 52‐week cumulative incidence of 16% for patients treated with sequential and/or combination treatment, 8% for patients treated only with anti‐PD1/PDL1 monotherapy and 7% for patients treated only with anti‐CTLA4 monotherapy.